DK0512002T3 - - Google Patents
Info
- Publication number
- DK0512002T3 DK0512002T3 DK91902866.2T DK91902866T DK0512002T3 DK 0512002 T3 DK0512002 T3 DK 0512002T3 DK 91902866 T DK91902866 T DK 91902866T DK 0512002 T3 DK0512002 T3 DK 0512002T3
- Authority
- DK
- Denmark
- Prior art keywords
- compound
- conjugate
- cyanide
- cyanogenic
- bladder
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nanotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB909001641A GB9001641D0 (en) | 1990-01-24 | 1990-01-24 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0512002T3 true DK0512002T3 (it) | 1997-02-10 |
Family
ID=10669837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK91902866.2T DK0512002T3 (it) | 1990-01-24 | 1991-01-24 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0512002B1 (it) |
| JP (2) | JPH05503933A (it) |
| AT (1) | ATE141516T1 (it) |
| DE (1) | DE69121555T2 (it) |
| DK (1) | DK0512002T3 (it) |
| ES (1) | ES2093697T3 (it) |
| GB (2) | GB9001641D0 (it) |
| GR (1) | GR3021729T3 (it) |
| WO (1) | WO1991011201A2 (it) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4233152A1 (de) | 1992-10-02 | 1994-04-07 | Behringwerke Ag | Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung |
| GB2300859B (en) * | 1993-01-15 | 1997-06-18 | Imp Cancer Res Tech | Compounds comprising a target cell-specific portion and a further portion |
| GB9300686D0 (en) * | 1993-01-15 | 1993-03-03 | Imp Cancer Res Tech | Compounds for targeting |
| GB9712370D0 (en) | 1997-06-14 | 1997-08-13 | Aepact Ltd | Therapeutic systems |
| EP0943680A1 (en) * | 1998-03-17 | 1999-09-22 | Boehringer Ingelheim International GmbH | Suicide gene therapy system for the treatment of brain tumours |
| GB2348203B (en) | 1998-11-04 | 2002-06-19 | Imp College Innovations Ltd | Solube beta-forms of prion proteins, methods of preparation and use |
| DK2029756T3 (en) | 2006-06-20 | 2017-02-13 | Transgene Sa | PROCEDURE FOR PREPARING POXVIRA AND POXVIRUS COMPOSITIONS |
| DK2150276T3 (da) | 2007-05-03 | 2014-08-18 | Agency Science Tech & Res | Antistoffer, som binder til et intracellulært prl-1- eller prl-3-polypeptid |
| CA2760465A1 (en) | 2009-05-12 | 2010-11-18 | Transgene Sa | Method for orthopoxvirus production and purification |
| EP2456461A1 (en) | 2009-07-21 | 2012-05-30 | Transgene SA | Enzymatic composition for the digestion of chicken embryos |
| DK3226894T3 (da) | 2014-12-01 | 2019-10-21 | Transgene Sa | Stabile flydende vacciniavirus-formuleringer |
| WO2017167350A1 (en) * | 2016-03-30 | 2017-10-05 | Horst Lindhofer | Multispecific antibodies for use in the treatment of a neoplasm of the urinary tract |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8528761D0 (en) * | 1985-11-22 | 1985-12-24 | Axon Healthcare Ltd | Enzyme-coupled antibodies |
| GB8705477D0 (en) * | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| WO1988006937A1 (en) * | 1987-03-19 | 1988-09-22 | Institut Elektrosvarki Imeni E.O.Patona Akademii N | Discharge device for magnetopulse processing and welding of metals |
| NZ225599A (en) * | 1987-08-04 | 1991-09-25 | Bristol Myers Co | Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells |
-
1990
- 1990-01-24 GB GB909001641A patent/GB9001641D0/en active Pending
-
1991
- 1991-01-24 DK DK91902866.2T patent/DK0512002T3/da active
- 1991-01-24 EP EP91902866A patent/EP0512002B1/en not_active Expired - Lifetime
- 1991-01-24 WO PCT/GB1991/000104 patent/WO1991011201A2/en active IP Right Grant
- 1991-01-24 ES ES91902866T patent/ES2093697T3/es not_active Expired - Lifetime
- 1991-01-24 JP JP3503137A patent/JPH05503933A/ja active Pending
- 1991-01-24 AT AT91902866T patent/ATE141516T1/de not_active IP Right Cessation
- 1991-01-24 DE DE69121555T patent/DE69121555T2/de not_active Expired - Fee Related
-
1992
- 1992-06-25 GB GB9213550A patent/GB2256198B/en not_active Revoked
-
1996
- 1996-11-20 GR GR960403124T patent/GR3021729T3/el unknown
-
2002
- 2002-04-10 JP JP2002108444A patent/JP2002322093A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP0512002A1 (en) | 1992-11-11 |
| JPH05503933A (ja) | 1993-06-24 |
| GB2256198A (en) | 1992-12-02 |
| GB9213550D0 (en) | 1992-09-23 |
| WO1991011201A2 (en) | 1991-08-08 |
| DE69121555D1 (de) | 1996-09-26 |
| GB2256198B (en) | 1994-01-12 |
| JP2002322093A (ja) | 2002-11-08 |
| ES2093697T3 (es) | 1997-01-01 |
| EP0512002B1 (en) | 1996-08-21 |
| ATE141516T1 (de) | 1996-09-15 |
| GB9001641D0 (en) | 1990-03-21 |
| DE69121555T2 (de) | 1997-05-22 |
| GR3021729T3 (en) | 1997-02-28 |
| WO1991011201A3 (en) | 1991-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0512002T3 (it) | ||
| JPH05501543A (ja) | 診断薬または治療薬の抗体ターゲティング | |
| LU91928I2 (fr) | Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®) | |
| GB2276623A (en) | Cytotoxic drug therapy | |
| EP0382796A1 (en) | Method for the preparation of antibody-fragment conjugates | |
| PT1157041E (pt) | Anticorpos para terapia e diagnostico de cancro | |
| LU91927I2 (fr) | Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®) | |
| AU1250483A (en) | Conjugate of enzyme and antibody | |
| EP0760685A4 (en) | PROCESS FOR RADIOTHERING PROTEINS FOR THE PURPOSE OF PERFORMING RADIOIMMUNODETECTION AND RADIOIMMUNOTHERAPY BASED ON RADIONUCLEIDES | |
| CA2329776A1 (en) | Antibody against lar phosphatase subunit | |
| HUT73669A (en) | Compounds for treating human diseases connected with supranormal intracellular enzyme-activity | |
| HK1046928A1 (en) | Veto cells effective in preventing graft rejectionand devoid of graft versus host potential | |
| NO177526C (no) | Fremgangsmåte for fremstilling av farmasöytisk aktive konjugater | |
| CA2284079A1 (en) | Immunotoxins and methods of inducing immune tolerance | |
| IL126803A0 (en) | Method and composition for reconforming multi-epitopic antigens to initiate an immune response | |
| FI97692B (fi) | Menetelmä terapeuttisesti käyttökelpoisen aktivaattori-kohdistusosa -konjugaatin ja esilääkkeen valmistamiseksi | |
| IL116511A0 (en) | Mutant enzymes | |
| Ip et al. | Increase in serum and tissue glycosyltransferases and glycosidases in tumor-bearing rats | |
| WO2000057911A3 (en) | Hapten-conjugated mammalian cells and methods of making and using thereof | |
| CA1168150A (en) | Targeting conjugates of albumin and therapeutic agents | |
| WO1996032137A3 (en) | Methods of inducing immune tolerance using immunotoxins | |
| AU3439799A (en) | Immunization against and treatment for infection by (h.pylori) | |
| AU3991899A (en) | Verotoxin b subunit for immunization | |
| IL116863A0 (en) | An immunoenzymatic conjugate its preparation and use | |
| Ahrén | Glucagon-like Peptide-l (7–36) amide Increases Cyclic AMP Accumulation in Normal Islets |